What factors affect a sufficient dose of nitrofurantino?
nitrophurantoin is an antibiotic generally used in the treatment of cystitis prevention, also known as urinary tract infections. Due to the serious side effects associated with its use, it is generally recommended only when the infection has not responded to the treatment of other antibiotics. Pediatric patients should have a significantly lower dose of nitrofurantoin than is recommended in adults, as well as patients with reduced liver function.
When using this drug to treat cystitis, the standard initial dose of adult nitrofurantinum is 50 to 100 mg administered perorally daily. The dual release of nitrofurantino is 100 mg given twice a day in adults, as is also recommended for children over 12 years of age. Younger children should be administered 5 to 7 mg per kg of body weight, up to 400 mg daily in four divided doses. Therapy can be stopped after seven days or at least three days after the urine becomes sterile.
nitrofurantoin is also used occasionally for cystitis overconspones in patientThe ones who had several recurrences of cystitis or for which cystitis may cause further health complications. Due to prophylactically, a sufficient dose of nitrofurantino should be between 50 and 100 mg collected at bedtime. In children, the dose may be 1 to 2 mg per kg body weight up to a maximum daily dose of 100 mg each day in one or two divided doses.
patients suffering from reduced liver function may be necessary to give lower dose of nitrofurantinum because the drug is strongly metabolized in the liver. Due to the risk of toxicity, alternatives to this drug should be considered in patients with reduced kidney, anuria or oliguria function. Because older patients are exposed to increased risk of this and other side effects, alternative drugs should be used in geriatric populations.
Other risks of nitrofurantino include the development of hemolytic anemia, which makes the drug unsuitable in tof pregnant mothers or in infants younger than one month. Patients with a history of liver damage, hepatitis or chostestatic jaundice should not take this medicine because several deaths have been reported in these populations. All patients taking nitrofurantoin should have regular liver enzyme tests during therapy. Patients taking nitrofurantoin for a long time, especially patients with anemia, diabetes, vitamin B deficiency, electrolyte imbalance or discardation is also at risk of irreversible or fatal damage to the peripheral nerve. Chronic use of nitrofurantinum is also associated with increased risk of pulmonary dysfunction, especially pulmonary fibrosis or interstitial pneumonitis, and should be monitored regularly.
Like most antibiotics, nitrofurantoin therapy may lead to diarrhea associated with Clostridium difficile. While generally mild, this condition is to strong life -threatening. If interruption of therapy does not reduce symptoms, it may be needed to be seriouslythe sewing of the intervention.